Akers Biosciences (AKER) Reports Q3 GAAP Loss of $0.23/Share

Akers Biosciences (NASDAQ: AKER) reported Q3 EPS of ($0.23), versus ($0.30) reported last year. Revenue for the quarter came in at $453.3 million, versus $344.7 million reported last year.

The Street was looking for a Q3 loss of $0.17 per share (one estimate).

For earnings history and earnings-related data on Akers Biosciences (AKER) click here.

You May Also Be Interested In

• Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
• UBS Reiterates Neutral Rating on Green Plains Renewable Energy (GPRE)
• IMF chief says global economy weathered Iran war shock well